DS-1 is a drug from the imidazopyridine family which is the first drug developed that acts as a GABAA receptor agonist selective for the α4β3δ subtype which is not targeted by other GABA agonists such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 should prove useful in the study of this receptor subtype.
This page contains content from the copyrighted Wikipedia article "DS-1 (drug)"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
